TY - JOUR
T1 - Patient-derived prostate cancer
T2 - From basic science to the clinic
AU - Risbridger, Gail P.
AU - Taylor, Renea A.
PY - 2016/8
Y1 - 2016/8
N2 - Systems that model cancer form the backbone of research discovery, and their accuracy and validity are a key determinant to ensure successful translation. In many tumour types, patient-derived specimens are an important model of choice for pre-clinical drug development. In this review, we consider why this has been such a challenge for prostate cancer, resulting in relatively few patient-derived xenografts (PDXs) of prostatic tumours compared to breast cancers, for example. Nevertheless, with only a few patient specimens and PDXs, we exemplify in three vignettes how important new clinical insights were obtained resulting in benefit for future men with prostate cancer.
AB - Systems that model cancer form the backbone of research discovery, and their accuracy and validity are a key determinant to ensure successful translation. In many tumour types, patient-derived specimens are an important model of choice for pre-clinical drug development. In this review, we consider why this has been such a challenge for prostate cancer, resulting in relatively few patient-derived xenografts (PDXs) of prostatic tumours compared to breast cancers, for example. Nevertheless, with only a few patient specimens and PDXs, we exemplify in three vignettes how important new clinical insights were obtained resulting in benefit for future men with prostate cancer.
UR - http://www.ncbi.nlm.nih.gov/pubmed/27177552
U2 - 10.1007/s12672-016-0266-1
DO - 10.1007/s12672-016-0266-1
M3 - Article
SN - 1868-8497
VL - 7
SP - 236
EP - 240
JO - Hormones and Cancer
JF - Hormones and Cancer
IS - 4
ER -